The startup develops CD24 enriched exosomes as a therapy for pulmonary and systemic diseases characterized by cytokine storms. This targeted approach aims to provide patients with effective treatment options that mitigate the severe inflammatory responses associated with these conditions.
Funding
$9.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Cytokine storms, characterized by excessive and unrestrained release of cytokines and chemokines, lead to severe hyper-activation of the immune system. This condition is a major health concern with high morbidity and mortality, often complicating critical illnesses such as acute respiratory distress syndrome (ARDS) and sepsis. Current treatments are limited, and there is a need for therapies that can effectively modulate the immune response without compromising the body's ability to fight infections.
Solution
Nano24 is a clinical-stage company developing CD24-enriched exosomes (EXO-CD24) as a novel immunomodulator for treating pulmonary and systemic diseases associated with cytokine storms. EXO-CD24 leverages nanotechnology to deliver CD24, an innate immune checkpoint protein, directly to the lungs via inhalation, suppressing the inflammatory response to tissue injuries. This targeted approach allows the immune system to differentiate between damage-associated molecular patterns (DAMPs) and pathogen-associated molecular patterns (PAMPs), attenuating immune activation triggered by DAMPs without interfering with the recognition of PAMPs. Clinical data from studies involving over 250 ARDS patients indicate that EXO-CD24 has an exceptional safety profile and promising efficacy, reducing the need for mechanical ventilation and ICU admissions.
Target Audience
The primary target audience includes healthcare providers and patients seeking innovative treatments for cytokine storm-related diseases, such as acute respiratory distress syndrome (ARDS), sepsis, and autoimmune disorders.
Features
- Utilizes exosomes, nano-sized lipid vesicles, to deliver CD24, a novel immunomodulator
- Targets the cytokine storm, a key complication in pulmonary and systemic diseases
- Administered via inhalation, providing a simple, non-invasive delivery method directly to the lungs
- Modulates the immune system by distinguishing between DAMPs and PAMPs
- Attenuates NFĸB activation, reducing overall immune activation
- Demonstrated safety and efficacy in clinical trials with ARDS patients
- Has potential application for treating a wide range of systemic diseases, including autoimmune conditions